Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab in Symptomatic Waldenstroms Macroglobulinaemia
NCT01142011Phase 2Unknown
- Sponsor
- Cancer Trials Australia
- Start
- Nov 2009
- Primary completion
- Jun 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of belimumab in Waldenstrom macroglobulinemia (WM), sponsored by Cancer Trials Australia. Status: unknown.
02
Drugs
belimumab
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT01142011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01142011.